Claims for Patent: 10,052,345

Summary for Patent: 10,052,345

Title:	Assays, methods and kits for predicting renal disease and personalized treatment strategies
Abstract:	Assays, methods and kits for predicting a subject\'s (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders.
Inventor(s):	Fornoni; Alessia (Coral Gables, FL), Burke; George William (Miami, FL), Merscher-Gomez; Sandra (Miami, FL)
Assignee:	University of Miami (Miami, FL)
Application Number:	13/879,892
Patent Claims:	1. An assay for identifying at least one therapeutic agent for treatment of focal segmental glomerulosclerosis (FSGS) in a subject, the assay comprising: (a) contacting a culture of an immortalized human podocyte cell line with an FSGS specific pool of sera from at least one subject having FSGS or at risk for recurrent FSGS, resulting in decreased SMPDL-3b expression relative to a level of SMPDL-3b expression in an immortalized human podocyte cell line contacted with sera from a subject not having FSGS; (b) contacting a first portion of the podocytes with a library of candidate therapeutic agents, wherein at least a second portion of the podocytes is not contacted with the library of candidate therapeutic agents; (C) analyzing SMPDL-3b expression in the first and second portions of the podocytes; (d) identifying at least on therapeutic agent from the library of candidate therapeutic agents that prevents decreased SMPDL-3b expression, restores SMPDL-3b expression, or preserves SMPDL-3b expression in the first portion of the podocytes relative to SMPDL-3b expression in the second portion of podocytes; and (e) correlating the candidate therapeutic agent's ability to prevent decreased SMPDL-3b expression, restore SMPDL-3b expression or preserve SMPDL-3b expression in the first portion of the podocytes relative to SMPDL-3b expression in the second portion of podocytes with an ability to treat recurrent FSGS in the subject. 2. An assay for predicting prior to subject's kidney transplantation the subject's response after the kidney transplantion to abatacept for treatment of focal segmental glomerulosclerosis (FSGS), the subject having FSGS and the assay comprising the steps of: (a) prior to kidney tansplantation, obtaining a biological sample comprising serum from the subject having FSGS; (b) contacting a first portion of the biological sample with a first culture of an immortalized human podocyte cell line in the presence of abatacept, and contacting a second portion of the biological sample with a second culture of the immortalized human podocyte cell in the absence of abatacept; (c) examining the first and second cultures of podocytes for at least one of: disruption of F-actin distribution, and cell blebbing; (d) correlating an absence of at least one of; disruption of F-actin distribution, and cell blebbing in the first culture of podocytes relative to the second culture of podocyte with a positive response to abatacept; and (e) if a positive response to abatacept was found in step (d), administering abatacept to the subject.

Details for Patent 10,052,345

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	12/23/2005		2030-10-19
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	07/29/2011		2030-10-19
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	06/07/2016		2030-10-19